Furthermore, the dual mTOR inhibitor, sapanisertib (MLN0128), was tested in a phase II clinical trial for patients with lung cancer, which is at stage IV or recurrent due to mutation in multiple genes related to cancer growth [192]. The gene discussed is MTOR; the disease is lung carcinoma.